NO2680873T3 - - Google Patents
Info
- Publication number
- NO2680873T3 NO2680873T3 NO12751994A NO12751994A NO2680873T3 NO 2680873 T3 NO2680873 T3 NO 2680873T3 NO 12751994 A NO12751994 A NO 12751994A NO 12751994 A NO12751994 A NO 12751994A NO 2680873 T3 NO2680873 T3 NO 2680873T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448807P | 2011-03-03 | 2011-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2680873T3 true NO2680873T3 (fr) | 2018-01-06 |
Family
ID=46758514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO12751994A NO2680873T3 (fr) | 2011-03-03 | 2012-03-02 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US8722619B2 (fr) |
| EP (2) | EP2680873B1 (fr) |
| JP (4) | JP5809296B2 (fr) |
| CN (2) | CN106279369B (fr) |
| CA (2) | CA3053850A1 (fr) |
| CY (2) | CY1119709T1 (fr) |
| DK (1) | DK2680873T3 (fr) |
| ES (1) | ES2645074T3 (fr) |
| FI (1) | FIC20240022I1 (fr) |
| FR (1) | FR24C1027I2 (fr) |
| HR (1) | HRP20171579T8 (fr) |
| HU (2) | HUE036778T2 (fr) |
| LT (2) | LT2680873T (fr) |
| NL (1) | NL301280I2 (fr) |
| NO (1) | NO2680873T3 (fr) |
| PL (1) | PL2680873T3 (fr) |
| PT (1) | PT2680873T (fr) |
| RS (1) | RS56426B1 (fr) |
| SI (1) | SI2680873T1 (fr) |
| SM (1) | SMT201700460T1 (fr) |
| WO (1) | WO2012119065A2 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2680873T (lt) | 2011-03-03 | 2017-11-27 | Cidara Therapeutics, Inc. | Priešgrybeliniai agentai ir jų panaudojimas |
| SI3677252T1 (sl) * | 2012-03-19 | 2024-02-29 | Cidara Therapeutics, Inc. | Sheme odmerjanja za spojine iz razreda ehinokandinov |
| WO2015035102A2 (fr) * | 2013-09-04 | 2015-03-12 | Cidara Therapeutics, Inc. | Compositions et méthodes pour le traitement d'infections fongiques |
| AU2015253484A1 (en) * | 2014-04-28 | 2016-10-06 | University Of Central Florida Research Foundation, Inc. | Compositions, methods of making a composition, and methods of use |
| WO2016201283A1 (fr) * | 2015-06-12 | 2016-12-15 | Cidara Therapeutics, Inc. | Agents antifongiques |
| WO2017049102A1 (fr) * | 2015-09-16 | 2017-03-23 | Cidara Therapeutics, Inc. | Méthodes de traitement d'infections fongiques |
| CN106674333B (zh) * | 2015-11-06 | 2020-10-27 | 博瑞生物医药（苏州）股份有限公司 | 一种环肽类抗真菌化合物及其制备方法 |
| EP3399995A4 (fr) | 2016-01-08 | 2019-08-21 | Cidara Therapeutics, Inc. | Procédés de prévention et de traitement d'infections à pneumocystis |
| EP4268896A3 (fr) * | 2016-03-16 | 2024-01-03 | Cidara Therapeutics, Inc. | Schémas posologiques pour le traitement d'infections fongiques |
| EP3512539A4 (fr) | 2016-09-13 | 2020-07-29 | Prothera Biologics, Inc. | Procédés de traitement d'une maladie pulmonaire à l'aide de protéines inhibitrices d'inter-alpha |
| WO2018102407A1 (fr) * | 2016-11-29 | 2018-06-07 | Cidara Therapeutics, Inc | Procédés de prévention d'infections fongiques |
| EP3577129A1 (fr) * | 2017-01-31 | 2019-12-11 | Cidara Therapeutics, Inc. | Procédés de traitement d'infections fongiques |
| BR112019022358A2 (pt) | 2017-04-25 | 2020-05-19 | Prothera Biologics Inc | métodos para quantificar proteínas inibidoras inter-alfa |
| CN111050798A (zh) * | 2017-07-12 | 2020-04-21 | 奇达拉治疗公司 | 用于治疗真菌感染的组合物和方法 |
| JP7373508B2 (ja) * | 2018-06-15 | 2023-11-02 | シダラ セラピューティクス インコーポレーテッド | エキノカンジン抗真菌剤の合成 |
| US12060439B2 (en) | 2018-10-25 | 2024-08-13 | Napp Pharmaceutical Group Limited | Polymorph of echinocandin antifungal agent |
| KR20220110513A (ko) | 2019-12-06 | 2022-08-08 | 상하이 센후이 메디슨 컴퍼니 리미티드 | 에키노칸딘 유사체 및 그 제조방법 |
| CA3219309A1 (fr) | 2021-06-03 | 2022-12-08 | Wei Jiang | Procede de preparation d'un derive d'anidulafungine |
| CN115850383A (zh) * | 2022-12-15 | 2023-03-28 | 江苏九阳生物制药有限公司 | 一种雷扎芬净纯化方法 |
| CN116903706B (zh) * | 2023-06-13 | 2024-05-17 | 深圳市祥根生物有限公司 | 一种棘白菌素类药物及其制备方法和用途 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427660A (en) | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
| US5166135A (en) | 1988-09-12 | 1992-11-24 | Merck & Company, Inc. | Method for the control of pneumocystis carinii |
| US6030944A (en) * | 1991-10-01 | 2000-02-29 | Merck & Co., Inc. | Cyclohexapeptidyl bisamine compounds |
| US5399552A (en) | 1991-10-17 | 1995-03-21 | Merck & Co, Inc | Antibiotic peptides bearing aminoalkylthioether moieties |
| US5378804A (en) | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US6268338B1 (en) | 1993-04-30 | 2001-07-31 | Merck & Co., Inc. | Cyclohexapeptidyl amine compounds |
| CA2161149A1 (fr) | 1993-05-04 | 1994-11-10 | James M. Balkovec | Ether-oxydes de cyclohexapeptidyle et d'aminoalkyle |
| US5948753A (en) | 1993-05-04 | 1999-09-07 | Merck & Co., Inc. | Cyclohexapeptidyl propanolamine compounds |
| AU7874494A (en) * | 1993-09-22 | 1995-04-10 | Merck & Co., Inc. | Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use |
| US5541160A (en) * | 1994-04-04 | 1996-07-30 | Merck & Co., Inc. | Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use |
| US5514651A (en) | 1994-09-16 | 1996-05-07 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US5516756A (en) | 1994-10-31 | 1996-05-14 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| CA2211138A1 (fr) | 1995-01-26 | 1996-08-01 | Merck & Co., Inc. | Nouveaux cyclohexapeptides antifongiques |
| US5652213A (en) * | 1995-05-26 | 1997-07-29 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| PE63998A1 (es) | 1996-04-19 | 1998-10-30 | Merck & Co Inc | Composiciones anti-fungosas |
| US6069126A (en) | 1996-09-12 | 2000-05-30 | Merck & Co., Inc. | Antifungal combination therapy |
| RU2001118849A (ru) * | 1998-12-09 | 2003-08-10 | Эли Лилли энд Компани (US) | Очистка циклопептидных соединений эхинокандина |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| HK1040369A1 (zh) | 1999-03-03 | 2002-06-07 | Eli Lilly And Company | 制备药物口服ecb配方和组合物的方法 |
| ES2433678T3 (es) | 1999-03-03 | 2013-12-12 | Eli Lilly & Company | Formulaciones farmacéuticas de equinocandina que contienen tensioactivos formadores de micelas |
| US6309622B1 (en) | 1999-03-26 | 2001-10-30 | Protech Professional Products, Inc. | Antimicrobial denture cleansing compositions |
| KR20010108469A (ko) | 1999-04-16 | 2001-12-07 | 후지야마 아키라 | 항진균 조성물 |
| US6610822B2 (en) | 2000-09-01 | 2003-08-26 | Merck & Co., Inc. | Purification process |
| HU0104790D0 (en) | 2001-11-08 | 2002-01-28 | Human Rt | Pharmaceutical combinations for topical application |
| US6991800B2 (en) | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| US20060276339A1 (en) | 2002-10-16 | 2006-12-07 | Windsor J B | Methods and compositions for increasing the efficacy of biologically-active ingredients |
| US6913759B2 (en) | 2003-03-11 | 2005-07-05 | Curatek Pharmaceuticals Holding, Inc. | Gel composition and method for treatment of vaginal infections |
| EP1654036B1 (fr) | 2003-07-22 | 2007-12-26 | Theravance, Inc. | Utilisation d'un agent antifongique a base d'echinocandines conjointement avec un agent antibacterien glycopeptidique |
| US20060140990A1 (en) | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
| EP1907588B1 (fr) | 2005-07-26 | 2013-06-05 | The University of Medicine and Dentistry of New Jersey | Analyses determinant la resistance a des medicaments de la classe des echinocandines |
| US20070231258A1 (en) * | 2006-03-31 | 2007-10-04 | Karyon Ctt Ltd. | Peptide conjugates |
| GB0702020D0 (en) | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
| US20090238867A1 (en) | 2007-12-13 | 2009-09-24 | Scott Jenkins | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same |
| US20100009009A1 (en) | 2008-07-10 | 2010-01-14 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
| GB0817121D0 (en) | 2008-09-18 | 2008-10-29 | Univ St Andrews | Anti-fungal therapy |
| PT2400951T (pt) | 2009-02-25 | 2018-11-26 | Mayne Pharma Llc | Composições de espuma tópica |
| CN102421790A (zh) * | 2009-05-07 | 2012-04-18 | 帝斯曼知识产权资产管理有限公司 | 制备环肽的方法 |
| HUE037592T2 (hu) | 2009-08-26 | 2018-09-28 | Bioelectron Tech Corp | Eljárások cerebrális ischemia megelõzésére és kezelésére |
| JP2013503179A (ja) | 2009-08-27 | 2013-01-31 | シーチェイド ファーマシューティカルズ，インコーポレーテッド | エキノキャンディン誘導体 |
| EP2525831B1 (fr) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Liens de promédicaments à base de carbamates liés à un support |
| LT2680873T (lt) | 2011-03-03 | 2017-11-27 | Cidara Therapeutics, Inc. | Priešgrybeliniai agentai ir jų panaudojimas |
| WO2013017691A1 (fr) | 2011-08-04 | 2013-02-07 | Medizinische Universität Innsbruck | Inhibiteurs de cahgtlp destinés à être utilisés dans le traitement de la candidiase |
| US8829053B2 (en) | 2011-12-07 | 2014-09-09 | Rochal Industries Llp | Biocidal compositions and methods of using the same |
| SI3677252T1 (sl) | 2012-03-19 | 2024-02-29 | Cidara Therapeutics, Inc. | Sheme odmerjanja za spojine iz razreda ehinokandinov |
| CN102766198A (zh) | 2012-05-04 | 2012-11-07 | 中国人民解放军第二军医大学 | 一种糖肽类抗真菌化合物及其制备方法与应用 |
| WO2014113693A1 (fr) | 2013-01-18 | 2014-07-24 | University Of Utah Research Foundation | Pompe osmotique à libération modifiée pour administration intravaginale de médicament réagissant au ph |
| WO2014124504A1 (fr) | 2013-02-13 | 2014-08-21 | Katholieke Universiteit Leuven Ku Leuven Research & Development | Compositions et méthodes de traitement de biofilms |
| AU2014233404A1 (en) | 2013-03-15 | 2015-10-08 | Chandraball BHATTACHARYA | Sugar-linker-drug conjugates |
| CN112656782A (zh) | 2013-05-01 | 2021-04-16 | 尼奥酷里私人有限公司 | 治疗细菌感染的方法 |
| WO2015035102A2 (fr) | 2013-09-04 | 2015-03-12 | Cidara Therapeutics, Inc. | Compositions et méthodes pour le traitement d'infections fongiques |
| WO2017049102A1 (fr) | 2015-09-16 | 2017-03-23 | Cidara Therapeutics, Inc. | Méthodes de traitement d'infections fongiques |
| WO2017049105A1 (fr) | 2015-09-16 | 2017-03-23 | Cidara Therapeutics, Inc. | Formulations pour le traitement d'infections fongiques |
| EP3399995A4 (fr) | 2016-01-08 | 2019-08-21 | Cidara Therapeutics, Inc. | Procédés de prévention et de traitement d'infections à pneumocystis |
| EP4268896A3 (fr) | 2016-03-16 | 2024-01-03 | Cidara Therapeutics, Inc. | Schémas posologiques pour le traitement d'infections fongiques |
| WO2018085200A1 (fr) | 2016-11-01 | 2018-05-11 | Cidara Therapeutics, Inc. | Méthodes à dose unique pour la prévention et le traitement d'infections fongiques |
| WO2018102407A1 (fr) | 2016-11-29 | 2018-06-07 | Cidara Therapeutics, Inc | Procédés de prévention d'infections fongiques |
| EP3577129A1 (fr) | 2017-01-31 | 2019-12-11 | Cidara Therapeutics, Inc. | Procédés de traitement d'infections fongiques |
| WO2018187574A1 (fr) | 2017-04-05 | 2018-10-11 | Cidara Therapeutics, Inc. | Compositions et procédés de traitement d'infections fongiques |
| WO2018191692A1 (fr) | 2017-04-14 | 2018-10-18 | Cidara Therapeutics, Inc. | Procédés de traitement d'infections fongiques |
| CN111050798A (zh) | 2017-07-12 | 2020-04-21 | 奇达拉治疗公司 | 用于治疗真菌感染的组合物和方法 |
| US20200164023A1 (en) | 2017-08-03 | 2020-05-28 | Cidara Therapeutics, Inc. | Methods for preventing and treating intra-abdominal candidiasis |
| JP7373508B2 (ja) | 2018-06-15 | 2023-11-02 | シダラ セラピューティクス インコーポレーテッド | エキノカンジン抗真菌剤の合成 |
-
2012
- 2012-03-02 LT LTEP12751994.0T patent/LT2680873T/lt unknown
- 2012-03-02 HR HRP20171579TT patent/HRP20171579T8/hr unknown
- 2012-03-02 CN CN201610692359.9A patent/CN106279369B/zh active Active
- 2012-03-02 HU HUE12751994A patent/HUE036778T2/hu unknown
- 2012-03-02 RS RS20171032A patent/RS56426B1/sr unknown
- 2012-03-02 JP JP2013556894A patent/JP5809296B2/ja active Active
- 2012-03-02 NO NO12751994A patent/NO2680873T3/no unknown
- 2012-03-02 WO PCT/US2012/027451 patent/WO2012119065A2/fr not_active Ceased
- 2012-03-02 ES ES12751994.0T patent/ES2645074T3/es active Active
- 2012-03-02 CA CA 3053850 patent/CA3053850A1/fr not_active Abandoned
- 2012-03-02 DK DK12751994.0T patent/DK2680873T3/en active
- 2012-03-02 PT PT127519940T patent/PT2680873T/pt unknown
- 2012-03-02 EP EP12751994.0A patent/EP2680873B1/fr active Active
- 2012-03-02 CA CA2865791A patent/CA2865791C/fr active Active
- 2012-03-02 SM SM20170460T patent/SMT201700460T1/it unknown
- 2012-03-02 SI SI201231096T patent/SI2680873T1/sl unknown
- 2012-03-02 EP EP17158336.2A patent/EP3192803B1/fr active Active
- 2012-03-02 CN CN201280021321.9A patent/CN103889221B/zh active Active
- 2012-03-02 PL PL12751994T patent/PL2680873T3/pl unknown
-
2013
- 2013-05-03 US US13/886,972 patent/US8722619B2/en active Active
-
2014
- 2014-04-01 US US14/242,192 patent/US9217014B2/en active Active
-
2015
- 2015-09-10 JP JP2015178029A patent/JP6111447B2/ja active Active
- 2015-11-24 US US14/950,801 patent/US9676821B2/en active Active
-
2017
- 2017-02-16 JP JP2017026954A patent/JP6302108B2/ja active Active
- 2017-05-18 US US15/598,913 patent/US20170253635A1/en not_active Abandoned
- 2017-10-23 CY CY20171101099T patent/CY1119709T1/el unknown
-
2018
- 2018-03-01 JP JP2018036159A patent/JP2018118977A/ja active Pending
-
2021
- 2021-07-01 US US17/365,188 patent/US12344680B2/en active Active
-
2024
- 2024-06-19 CY CY2024022C patent/CY2024022I2/el unknown
- 2024-06-19 FI FIC20240022C patent/FIC20240022I1/fi unknown
- 2024-06-19 LT LTPA2024520C patent/LTPA2024520I1/lt unknown
- 2024-06-20 HU HUS2400021C patent/HUS2400021I1/hu unknown
- 2024-06-20 FR FR24C1027C patent/FR24C1027I2/fr active Active
- 2024-06-21 NL NL301280C patent/NL301280I2/nl unknown
-
2025
- 2025-06-03 US US19/226,762 patent/US20250289852A1/en active Pending